Table 5 Selected examples of Academia, Pharma, and Pharma-Academia initiatives concerning genomics and drug development.
From: Improving the odds of drug development success through human genomics: modelling study
Initiative | Partners | Drug development model | Aims |
|---|---|---|---|
Accelerating Drug Development and Repurposing Incubator at Vanderbilt Universitya | Multiple departments at Vanderbilt University Medical Centre | Academic incubator | De-identified genotype data linked to de-identified demographic and health record data to aid precision drug development and drug repurposing |
DECODE Geneticsb | Decode is a subsidiary of Amgen, a biopharmaceutical company | Within-company | Discover genetic variation underlying human disease in the Icelandic population with the aim of diagnosing, treating and preventing disease |
Open Targetsc | GSK, Biogen, European Bioinformatics Institute, Wellcome Trust Sanger Institute | Pre-competitive, open access | Public-private initiative based on the use of genomics for drug target validation |
Astra Zeneca Centre for Genomics Research | Human Longevity, Inc Wellcome Trust Sanger Institute Institute for Molecular Medicine, Finland | Within-company | ‘Integrated genomics initiative to transform drug discovery and development across (AZ’s) entire therapeutic pipeline’ |
Eisai Andover Innovative Medicines Institutee | Seeking collaborations with external scientific partners | Pre-competitive research consortia | ‘Executing novel therapeutic targets validated by human genetics’ |
Regeneron Genetics Centref | Geisinger Health System, and other health service and academic partners | Within-company | ‘Comparing genetic information against medical histories.to develop new means of diagnosing, preventing and/or treating medical conditions’ |
GSK-Regeneron UK Biobank Partnerhshipg | GSK, Regeneron and UK Biobank | Industry academia partnership, with 9 month exclusivity period for Pharma partners | Exome sequencing of stored DNA from UK Biobank participants: 50,000 samples in year 1, 500,000 by year 3. |
